Merck's Cidara Buyout Is An Opportunistic Win For Both Parties - Here's Why

Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...

Merck Stock Falls. Sales of Key Products Missed Estimates.

Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer drug.
PharmExec

Merck to Acquire Cidara for $9.2 Billion

Merck's acquisition of Cidara Therapeutics for $9.2 billion focuses on CD388, a promising antiviral for influenza prevention.

Wall Street Breakfast Podcast: Merck Talks Send Cidara Soaring

Merck seen nearing acquisition of Cidara Therapeutics in deal potentially above $3.3 billion. U.S., Argentina to open markets ...
EconoTimes

Merck KGaA Tightens 2025 Outlook as Healthcare and Life Science Drive Growth

Merck KGaA (ETR: MRCG) strengthened its full-year 2025 outlook after posting higher third-quarter earnings, supported by ...
Blockonomi

Merck (MRK) Stock: Heart Drug Trial Results Push Shares Up

Shares rise 8.5% on enlicitide decanoate Phase 3 data showing LDL reduction. Q3 earnings beat at $2.58/share with $17.3B ...

Merck (MRK) Is Up 8.5% After Promising Oral PCSK9 Cholesterol Drug Trial Results – Has The Bull Case Changed?

In recent days, Merck announced pivotal Phase 3 trial results showing its once-daily oral PCSK9 inhibitor, enlicitide, reduced low-density lipoprotein cholesterol by more than half in patients with ...
FierceBiotech

Merck Establishes Joint Venture with Supera Farma to Commercialize Innovative Pharmaceutical Products and Branded Generics

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the formation of a new joint venture (JV) with Supera Farma ...